NF2 and mesothelioma: Therefore, the hypothesis that FAK inhibitors exhibit synthetic lethality with NF2 mutations is not fully confirmed; however, its biomarker needs to be identified since FAK inhibitors are effective in a subset of mesothelioma cells with high FAK activity, and the study has identified LUM, a regulator of the integrin pathway, as a candidate (Tranchant et al., 2018).